hVIVO gets HSE clearance, launches new lab services
Specialist contract research organisation launched the full suite of services provided by its hLAB division - a highly specialised virology and immunology laboratory supporting preclinical and clinical drug development - on Monday.
The AIM-traded firm said that with its new facility in Canary Wharf, it had tripled hLAB's capacity, allowing the division to offer standalone laboratory services for the first time.
It had already secured three standalone contracts in 2024, including its first major field study.
hVIVO said hLAB's expanded capabilities included the recent completion of a containment level three (CL-3) laboratory, which had received Health and Safety Executive (HSE) clearance.
The new lab would enable the company to work with hazard group three pathogens, further enhancing its virology and immunology offerings.
In addition, hLAB had broadened its assay portfolio, providing critical services for new pathogens such as omicron, human metapneumovirus (hMPV), dengue, and a wider range of influenza, RSV, and HRV strains.
The division also expanded its field trial biologistics services, enabling bespoke sample collection kits for multinational field studies.
Additionally, hLAB had launched its biobank services, approved by the UK Research Ethics Committee, creating a comprehensive repository of human biological samples to support innovation in vaccine development, immunology, and respiratory research.
At 1044 BST, shares in hVIVO were down 0.11% at 28.3p.
Reporting by Josh White for Sharecast.com.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.